- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
May 26, 2022Shira Shapiro Named Woman of Promise By The Pearl Society
-
May 12, 2022Robins Kaplan Practice Group, Attorney Recognized in Elite Trial Lawyers Awards
-
May 9, 2022Six Partners Recognized as “IP Stars” by Managing Intellectual Property
-
June 2, 2022Hennepin County Bar Foundation 2022 Bar Benefit
-
June 2, 2022Lawyers Concerned for Lawyers 2022 Stepping Up Breakfast
-
June 2, 2022YWCA Minneapolis Empower Possible
-
May 24, 2022Briefly: Seeking Fees and Costs While on Appeal
-
May 19, 202211th Circ. Ban On Service Awards May Inhibit Class Actions
-
May 13, 2022Trademark Applications and the Murky Waters of Subject Matter Jurisdiction
-
May 27, 2022Unexpectedly Strong Retail Sales Pull Markets Back from the Brink
-
May 26, 2022Fed Minutes Show Inflation-Fighting Commitment, Spur Market Rally
-
May 25, 2022Mining Giant Glencore Fined $1.1B Over Global Bribery and Price Manipulation Scheme
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
GENERICally Speaking Hatch Waxman Bulletin
The Hatch-Waxman Litigation practice group at Robins Kaplan LLP is pleased to offer the latest edition of their quarterly publication regarding ANDA patent litigation issues and the generics business.
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
The Spring 2022 issue of the GENERICally Speaking email campaign provides you and your company with some of the knowledge beneficial to remaining attentive to the complexity of ANDA patent litigation.
In this issue:
- GlaxoSmithKline LLC v. Teva Pharms. USA, Inc.
Coreg® (carvedilol)
Defendant’s petition for rehearing en banc, seeking review of the Federal Circuit decision to vacate JMOL based on Defendant’s “skinny label” and reinstate the underlying jury verdict and damages award, was denied. - Adapt Pharma Operations Ltd. v. Teva Pharms. USA, Inc.
Narcan® (naloxone)
The Federal Circuit affirmed the district court’s opinion after finding: (i) that a POSA would have been motivated to combine the prior-art references to arrive at the claimed invention; (ii) that the prior art, as a whole, did not teach away from the claimed invention; and (iii) the appropriate weight was given to the lack of secondary considerations in the record evidence. - Novartis Pharms. Corp. v. Accord Healthcare, Inc.
Gilenya® (fingolimod HCl)
Finding of adequate written description of a negative limitation affirmed based on crediting expert testimony on the knowledge and perspective of a POSA. - Genentech, Inc. v. Sandoz, Inc.
Esbriet® (pirfenidone)
After a three-day bench trial, the court found that Sandoz did not induce infringement of either set of patents-in-suit, that one set of patents directed to liver-function tests was invalid as obvious, and that another set of patents directed to drug-drug interactions was not invalid. - Bausch Health Ireland Ltd. v. Mylan Labs. Ltd.
Trulance® (plecanatide)
Defendants’ motion to dismiss was granted in part on grounds of personal jurisdiction, and the case transferred to the Northern District of West Virginia. - Horizon Medicines LLC v. Dr. Reddy’s Labs., Inc.
Vimovo® (naproxen/esomeprazole magnesium)
Because effective esomeprazole required by the claims at issue did not materially differ from the effective uncoated PPI claims in a prior litigation, Plaintiffs were barred from proceeding on the basis of issue preclusion. - Azurity Pharms., Inc. v. Alkem Labs., Ltd.
Firvanq® (vancomycin HCl)
Taking all inferences in Plaintiff’s favor as the non-moving party, the court could not conclude that the undisputed facts precluded infringement and denied Defendant’s motion for judgment on the pleadings. - Amarin Pharm., Inc. v. Hikma Pharms. USA Inc.
Vascepa® (icosapent ethyl)
In view of Defendant’s skinny label, which removed from the package insert of the accused product the indication that is the subject of the patents-in-suit, the court granted Defendant’s motion to dismiss.
Relevant ANDA Updates highlighted in this issue:
Related Professionals
Reported settlements in federal district court cases
Federal district court cases that are filed pursuant to the Hatch-Waxman Act
New Drug Applications and 505(b)(2) Applications
Abbreviated New Drug Applications and 505(b)(2) Applications
Esbriet® (pirfenidone)
Coreg® (carvedilol)
Trulance® (plecanatide)
Vimovo® (naproxen/esomeprazole magnesium)
Narcan® (naloxone)
Firvanq® (vancomycin HCl)
Vascepa® (icosapent ethyl)
Gilenya® (fingolimod HCl)
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.